Hanne Lindegaard

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

Merete Lund Hetland, Ib Jarle Christensen, Ulrik Tarp et al. · Arthritis & Rheumatism · 2009 · 541 citations

Medicine, Internal Medicine, Pharmacotherapy +14

MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)

Merete Lund Hetland, B Ejbjerg, Søren Jacobsen et al. · Annals of the Rheumatic Diseases · 2008 · 366 citations

Medicine, Clinical Sciences, Immunology +17

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Bente Glintborg, Inge Juul Sørensen, Anne Gitte Loft et al. · Annals of the Rheumatic Diseases · 2017 · 249 citations

Medicine, Clinical Sciences, Internal Medicine +17

Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry

Bente Glintborg, Mikkel Østergaard, Niels Steen Krogh et al. · Arthritis & Rheumatism · 2013 · 203 citations

Medicine, Immunology, Pharmacotherapy +11

Radiographic progression and remission rates in early rheumatoid arthritis – MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial

Merete Lund Hetland, K. Stengaard‐Pedersen, Peter Junker et al. · Annals of the Rheumatic Diseases · 2010 · 188 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17